Companies › Vantive Health
1 active drug program in 1 registered trial: 1 Phase 3; Genitourinary; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Prismocitrate 18 Citrate-based anticoagulant for regional citrate anticoagulation (RCA) in extracorporeal c | – | Phase 3 | Regional Citrate Anticoagulation (RCA) | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05399537 | Prismocitrate 18 | Phase 3 | Regional Citrate Anticoagulation (RCA) | Genitourinary | Jan 2027 |
No annotated target.
–
Fertility Center of Las Vegas Zydus Lifesciences Granata Bio Dimerix Bioscience Chengdu Qingshan Likang Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.